CELETTI, ANGELA
CELETTI, ANGELA
Istituto di Endocrinologia e Oncologia Sperimentale ''G. Salvatore'' - IEOS
Mono(ADP-ribosyl)ation enzymes and NAD+ metabolism. A Focus on Diseases and Therapeutic Perspectives
2021 Poltronieri, P; Celetti, A; Palazzo, L
Analysis of CCDC6 as a novel biomarker for the clinical use of PARP1 inhibitors in malignant pleural mesothelioma
2019 Morra, F; Merolla, F; D'Abbiero, D; Ilardi, G; Campione, S; Monaco, R; Guggino, G; Ambrosio, F; Staibano, S; Cerrato, A; Visconti, R; Celetti, A
CAF-1 subunits levels suggest combined treatments with PARP-inhibitors and ionizing radiation in advanced HNSCC
2019 Morra F.; Merolla F.; Picardi I.; Russo D.; Ilardi G.; Varricchio S.; Liotti F.; Pacelli R.; Palazzo L.; Mascolo M.; Celetti A.; Staibano S.
CCDC6 and USP7 expression levels suggest novel treatment options in high-grade urothelial bladder cancer 11 Medical and Health Sciences 1112 Oncology and Carcinogenesis 06 Biological Sciences 0601 Biochemistry and Cell Biology
2019 Morra F.; Merolla F.; Criscuolo D.; Insabato L.; Giannella R.; Ilardi G.; Cerrato A.; Visconti R.; Staibano S.; Celetti A.
Identification of novel biomarkers of homologous recombination defect in DNA repair to predict sensitivity of prostate cancer cells to PARP-inhibitors
2019 Criscuolo D.; Morra F.; Giannella R.; Cerrato A.; Celetti A.
New combinatorial strategies to improve the PARP inhibitors efficacy in the urothelial bladder Cancer treatment
2019 Criscuolo D.; Morra F.; Giannella R.; Visconti R.; Cerrato A.; Celetti A.
NSCLC Mutated Isoforms of CCDC6 Affect the Intracellular Distribution of the Wild Type Protein Promoting Cisplatinum Resistance and PARP Inhibitors Sensitivity in Lung Cancer Cells.
2019 Cerrato A; Morra F; Di Domenico I; Celetti A.
Epigenetics of oral and oropharyngeal cancers (Review)
2018 Russo, D; Merolla, F; Varricchio, S; Salzano, G; Zarrilli, G; Mascolo, M; Strazzullo, V; Di Crescenzo, Rm; Celetti, A; Ilardi, G
The rationale for druggability of CCDC6-tyrosine kinase fusions in lung cancer
2018 Cerrato, Aniello; Visconti, Roberta; Celetti, Angela
CCDC6: The identity of a protein known to be partner in fusion
2017 Cerrato A.; Merolla F.; Morra F.; Celetti A.
FKBP51 immunohistochemical expression: A new prognostic biomarker for OSCC?
2017 Daniela, R; Francesco, M; Mascolo, M; Ilardi, G; Romano, S; Varricchio, S; Napolitano, V; Celetti, A; Postiglione, L; Di Lorenzo, Pp; Califano, L; Dell'Aversana, Go; Astarita, F; Romano, Mf; Staibano, S
The between now and then of lung cancer chemotherapy and immunotherapy
2017 Visconti, R; Morra, F; Guggino, G; Celetti, A
The combined effect of USP7 inhibitors and PARP inhibitors in hormone-sensitive and castration-resistant prostate cancer cells.
2017 Morra, Francesco; Merolla, Francesco; Napolitano, Virginia; Ilardi, Gennaro; Miro, Caterina; Paladino, Simona; Staibano, Stefania; Cerrato, Aniello; Celetti, Angela
USP7 inhibitors, downregulating CCDC6, sensitize lung neuroendocrine cancer cells to PARP-inhibitor drugs
2017 Malapelle U.; Morra F.; Ilardi G.; Visconti R.; Merolla F.; Cerrato A.; Napolitano V.; Monaco R.; Guggino G.; Monaco G.; Staibano S.; Troncone G.; Celetti A.
MAPK15 upregulation promotes cell proliferation and prevents DNA damage in male germ cell tumors
2016 Rossi, M; Colecchia, D; Ilardi, G; Acunzo, M; Nigita, G; Sasdelli, F; Celetti, A; Strambi, A; Staibano, S; Croce, Cm; Chiariello, M
Nucleotide excision repair and head and neck cancers
2016 Merolla, Francesco; Mascolo, Massimo; Ilardi, Gennaro; Siano, Maria; Russo, Daniela; Graziano, Vincenzo; Celetti, Angela; Staibano, Stefania
Nucleotide Excision Repair and head and neck cancers.
2016 Merolla, Francesco; Mascolo, Massimo; Ilardi, Gennaro; Siano, Maria; Russo, Daniela; Graziano, Vincenzo; Celetti, Angela; Staibano, Stefania
Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: The rationale for their inclusion in the clinic
2016 Cerrato, A; Morra, F; Celetti, A
CCDC6 (coiled-coil domain containing 6)
2015 Morra, F; Miro, C; Napolitano, V; Merolla, F; Celetti, A
Ccdc6 knock-in mice develop thyroid hyperplasia associated to an enhanced CREB1 activity.
2015 Leone V; Langella C; Esposito F; Arra C; Palma G; Rea D; Paciello O; Merolla F; De Biase D; Papparella S; Celetti A; Fusco A;.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Mono(ADP-ribosyl)ation enzymes and NAD+ metabolism. A Focus on Diseases and Therapeutic Perspectives | 1-gen-2021 | Poltronieri, P; Celetti, A; Palazzo, L | |
| Analysis of CCDC6 as a novel biomarker for the clinical use of PARP1 inhibitors in malignant pleural mesothelioma | 1-gen-2019 | Morra, F; Merolla, F; D'Abbiero, D; Ilardi, G; Campione, S; Monaco, R; Guggino, G; Ambrosio, F; Staibano, S; Cerrato, A; Visconti, R; Celetti, A | |
| CAF-1 subunits levels suggest combined treatments with PARP-inhibitors and ionizing radiation in advanced HNSCC | 1-gen-2019 | Morra F.; Merolla F.; Picardi I.; Russo D.; Ilardi G.; Varricchio S.; Liotti F.; Pacelli R.; Palazzo L.; Mascolo M.; Celetti A.; Staibano S. | |
| CCDC6 and USP7 expression levels suggest novel treatment options in high-grade urothelial bladder cancer 11 Medical and Health Sciences 1112 Oncology and Carcinogenesis 06 Biological Sciences 0601 Biochemistry and Cell Biology | 1-gen-2019 | Morra F.; Merolla F.; Criscuolo D.; Insabato L.; Giannella R.; Ilardi G.; Cerrato A.; Visconti R.; Staibano S.; Celetti A. | |
| Identification of novel biomarkers of homologous recombination defect in DNA repair to predict sensitivity of prostate cancer cells to PARP-inhibitors | 1-gen-2019 | Criscuolo D.; Morra F.; Giannella R.; Cerrato A.; Celetti A. | |
| New combinatorial strategies to improve the PARP inhibitors efficacy in the urothelial bladder Cancer treatment | 1-gen-2019 | Criscuolo D.; Morra F.; Giannella R.; Visconti R.; Cerrato A.; Celetti A. | |
| NSCLC Mutated Isoforms of CCDC6 Affect the Intracellular Distribution of the Wild Type Protein Promoting Cisplatinum Resistance and PARP Inhibitors Sensitivity in Lung Cancer Cells. | 1-gen-2019 | Cerrato A; Morra F; Di Domenico I; Celetti A. | |
| Epigenetics of oral and oropharyngeal cancers (Review) | 1-gen-2018 | Russo, D; Merolla, F; Varricchio, S; Salzano, G; Zarrilli, G; Mascolo, M; Strazzullo, V; Di Crescenzo, Rm; Celetti, A; Ilardi, G | |
| The rationale for druggability of CCDC6-tyrosine kinase fusions in lung cancer | 1-gen-2018 | Cerrato, Aniello; Visconti, Roberta; Celetti, Angela | |
| CCDC6: The identity of a protein known to be partner in fusion | 1-gen-2017 | Cerrato A.; Merolla F.; Morra F.; Celetti A. | |
| FKBP51 immunohistochemical expression: A new prognostic biomarker for OSCC? | 1-gen-2017 | Daniela, R; Francesco, M; Mascolo, M; Ilardi, G; Romano, S; Varricchio, S; Napolitano, V; Celetti, A; Postiglione, L; Di Lorenzo, Pp; Califano, L; Dell'Aversana, Go; Astarita, F; Romano, Mf; Staibano, S | |
| The between now and then of lung cancer chemotherapy and immunotherapy | 1-gen-2017 | Visconti, R; Morra, F; Guggino, G; Celetti, A | |
| The combined effect of USP7 inhibitors and PARP inhibitors in hormone-sensitive and castration-resistant prostate cancer cells. | 1-gen-2017 | Morra, Francesco; Merolla, Francesco; Napolitano, Virginia; Ilardi, Gennaro; Miro, Caterina; Paladino, Simona; Staibano, Stefania; Cerrato, Aniello; Celetti, Angela | |
| USP7 inhibitors, downregulating CCDC6, sensitize lung neuroendocrine cancer cells to PARP-inhibitor drugs | 1-gen-2017 | Malapelle U.; Morra F.; Ilardi G.; Visconti R.; Merolla F.; Cerrato A.; Napolitano V.; Monaco R.; Guggino G.; Monaco G.; Staibano S.; Troncone G.; Celetti A. | |
| MAPK15 upregulation promotes cell proliferation and prevents DNA damage in male germ cell tumors | 1-gen-2016 | Rossi, M; Colecchia, D; Ilardi, G; Acunzo, M; Nigita, G; Sasdelli, F; Celetti, A; Strambi, A; Staibano, S; Croce, Cm; Chiariello, M | |
| Nucleotide excision repair and head and neck cancers | 1-gen-2016 | Merolla, Francesco; Mascolo, Massimo; Ilardi, Gennaro; Siano, Maria; Russo, Daniela; Graziano, Vincenzo; Celetti, Angela; Staibano, Stefania | |
| Nucleotide Excision Repair and head and neck cancers. | 1-gen-2016 | Merolla, Francesco; Mascolo, Massimo; Ilardi, Gennaro; Siano, Maria; Russo, Daniela; Graziano, Vincenzo; Celetti, Angela; Staibano, Stefania | |
| Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: The rationale for their inclusion in the clinic | 1-gen-2016 | Cerrato, A; Morra, F; Celetti, A | |
| CCDC6 (coiled-coil domain containing 6) | 1-gen-2015 | Morra, F; Miro, C; Napolitano, V; Merolla, F; Celetti, A | |
| Ccdc6 knock-in mice develop thyroid hyperplasia associated to an enhanced CREB1 activity. | 1-gen-2015 | Leone V; Langella C; Esposito F; Arra C; Palma G; Rea D; Paciello O; Merolla F; De Biase D; Papparella S; Celetti A; Fusco A;. |